Loading...
01/11 10:30
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call shows promising signs of future growth with strong R&D results and expansion plans, especially in core markets. The company's focus on innovative products like wafer-level chip scale sensors and advanced magnetic switch sensors is expected to drive sales. While some responses were vague, the overall sentiment from the Q&A indicates optimism, particularly with upcoming growth drivers and industry recovery. The anticipation of significant cash flow savings and a strong pipeline further supports a positive outlook for stock price movement.
Revenue Revenue increased 4% quarter-over-quarter sequentially and decreased 6% year-over-year. The year-over-year decrease was due to a 68% decrease in contract R&D revenue, partially offset by a 1% increase in product sales. Contract R&D was 3% of revenue. The year-over-year increase in product sales was due to a 21% increase in nondefense sales, partially offset by a 64% decrease in defense sales which can be volatile because of defense procurement cycles.
Gross Margin Gross margin decreased to 78% from 86% in the prior year quarter due to a less profitable product mix and strong distributor sales, which tend to have lower margins than direct sales.
Total Expenses Total expenses decreased 7% for the second quarter of fiscal 2026 compared to the second quarter of fiscal 2025 due to a 3% increase in R&D expense and a 23% decrease in SG&A. The increase in R&D was due to increased new product development. The decrease in SG&A was primarily due to the timing of sales and marketing activities and reassignment of some SG&A resources to manufacturing and new product development.
Tax Rate Tax rate increased to 20% for the second quarter of fiscal 2026 compared to 17% for the second quarter of fiscal 2025, primarily due to the noncash impact of tax law changes on certain tax deductions this fiscal year.
Net Income Net income for the second quarter of fiscal 2026 was $3.31 million or $0.68 per diluted share compared to $4.03 million or $0.83 per share for the prior year quarter. The decrease in net income for the quarter was primarily due to decreased revenue, lower margins and a higher tax rate compared to a year ago, partially offset by decreased expenses.
Profitability Metrics Operating margin was 58%, pretax margin was 65% and net margin was 52%.
Cash Flow from Operations Cash flow from operations was $7.98 million in the first 6 months of the fiscal year. Accounts receivable decreased $1.1 million, primarily due to the timing of customer payments. Prepaid expenses and other assets increased by $730,000 primarily due to an increase in accrued bond interest and a decrease in federal and state taxes due.
Fixed Asset Purchases Fixed asset purchases were $1.13 million for the first half of the fiscal year. Most of that was for a cluster of production equipment, which arrived in July. The equipment was successfully installed in the past quarter and deployment is expected to be completed by the end of this fiscal year.
New Equipment and R&D: Installation of a new equipment cluster and expanded production area to increase capacity and capabilities, including wafer-level chip scale packaging for smaller and more precise parts.
New Products: Launched three new products: a rotation sensor for robotics and utility meters, a data coupler for motor control and energy conversion, and a wafer-level chip scale voltage regulator for harsh environments.
Medical Devices Market: Highlighted new wafer-level chip scale parts for implantable medical devices and surgical robots, high-sensitivity sensors for navigation, and nano power sensors for battery-powered devices at a trade show in Minneapolis.
Revenue and Sales: 4% sequential increase in revenue driven by distributor and nondefense sales, despite a decrease in defense sales. Gross margin decreased to 78% due to less profitable product mix.
Expenses and Tax: 7% decrease in total expenses year-over-year due to a 23% decrease in SG&A and a 3% increase in R&D expenses. Tax rate increased to 20% due to tax law changes, but advanced manufacturing tax credits are expected to offset this.
Production Expansion: Fixed asset purchases of $1.13 million for production equipment, with an additional $1-$1.5 million expected for further expansion.
Focus on High-Value Markets: R&D strategy targets high-value markets such as medical devices, electric vehicles, robotics, and AI-driven factories.
Trade Show Investments: Participation in trade shows to promote products and generate leads, particularly in the medical devices sector.
Economic Environment Uncertainties: The company acknowledges uncertainties related to the economic environments in the industries they serve, which could impact future sales and revenue.
Defense Sales Volatility: Defense sales decreased by 64% year-over-year due to the volatile nature of defense procurement cycles, which could impact revenue stability.
Gross Margin Decline: Gross margin decreased to 78% from 86% in the prior year quarter due to a less profitable product mix and strong distributor sales, which tend to have lower margins than direct sales.
Tax Law Changes: The company experienced a higher tax rate (20% compared to 17% in the prior year quarter) due to noncash impacts of tax law changes, which could affect net income.
R&D Revenue Decline: Contract R&D revenue decreased by 68% year-over-year, which could impact the company's ability to fund future innovations.
Production Expansion Costs: The company expects to spend an additional $1 million to $1.5 million on fixed assets in the next six months to complete production expansion, which could strain cash flow.
Tax Rate Projections: The company expects a full-year tax rate of between 16% and 17% for the current fiscal year, supported by advanced manufacturing investment tax credits of $700,000 to $1 million. For the next fiscal year, the effective tax rate is also projected to remain at approximately 16% to 17%.
Capital Expenditures: The company plans to spend an additional $1 million to $1.5 million on fixed assets in the last six months of the fiscal year to complete production expansion.
Production Expansion: The installation of new production equipment is expected to be completed by the end of the fiscal year, increasing capacity and capabilities, including in-house wafer-level chip scale packaging.
R&D and Product Development: The company plans to leverage new equipment to accelerate product development, focusing on high-value markets such as medical devices, electric and autonomous vehicles, advanced robotics, and AI-driven factories. Three new products were launched in the past quarter, and further growth is anticipated through continued innovation.
Market Trends and Sales Outlook: The company is optimistic about future sales growth, particularly in the medical devices market, supported by recent trade show participation and new product introductions tailored for miniaturization and reliability in medical applications.
The selected topic was not discussed during the call.
The earnings call shows promising signs of future growth with strong R&D results and expansion plans, especially in core markets. The company's focus on innovative products like wafer-level chip scale sensors and advanced magnetic switch sensors is expected to drive sales. While some responses were vague, the overall sentiment from the Q&A indicates optimism, particularly with upcoming growth drivers and industry recovery. The anticipation of significant cash flow savings and a strong pipeline further supports a positive outlook for stock price movement.
The earnings call highlights strong financial performance with comprehensive income and positive operating cash flow, despite lower margins. The Q&A reveals growth expectations in the PUF business and potential in replacing rare earth metals. Strategic investments in wafer-scale packaging and patents on SOT RAM are promising. Although management was vague on certain reporting aspects, the overall sentiment is positive with anticipated growth in military orders and new market expansions, supporting a positive stock price movement.
The earnings call highlights strong financial metrics with high margins, a positive revenue outlook, and optimism in future demand, especially in medical and AI sectors. New product introductions and high isolation voltage devices are well-received. Despite increased expenses and a decrease in fiscal year revenue, the company's strategic R&D investments and strong profitability metrics suggest positive sentiment. The Q&A section indicates confidence in new business and product expansion. The quarterly dividend and lack of negative guidance further support a positive outlook, projecting a stock price increase of 2% to 8%.
The earnings call reveals significant challenges: a 25% revenue drop, increased expenses, and economic uncertainties. Despite a gross margin improvement and optimistic market demand outlook, the absence of a share repurchase program and concerns over inventory management, competitive pressures, and regulatory issues weigh heavily. The Q&A section highlights inventory gluts and vague responses on critical business areas, further dampening sentiment. These factors, coupled with decreased net income and increased expenses, suggest a negative stock price movement in the short term.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
